Growth Hormone Study in Adults With Prader-Willi Syndrome
ConditionPrader-Willi Syndrome
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorErasmus Medical Center
About this trial
The overall objective of this study is to measure the effect of growth hormone (GH) treatment on physical and psychosocial health in adults with Prader-Willi syndrome. Adults with PWS who have not been treated with GH during the past three years and who will start with GH treatment as part of regular patient care will be asked for informed consent to participate in this open-label prospective cohort study. We hypothesize that growth hormone treatment will improve the physical and psychosocial health.
Eligibility criteria
Qualifiers
The patient is diagnosed with Prader-Willi syndrome (genetically confirmed)
Disqualifiers
Non cooperative behaviour
Pregnancy
Known malignancies
Poorly controlled diabetes (HbA1c > 64 mmol/mol (8%))
Trial design
Treatments tested in this trial
- Not listed
Trial groups
25 Participants
are grouped into 1 trial groupSponsors and collaborators
Erasmus Medical Center
Lead sponsor
Foundation for Prader-Willi Research
Collaborator
Prader-Willi Fonds
Collaborator
Source ClinicalTrials.gov